Kala Pharmaceuticals Inc Gets a Buy Rating from Wedbush

By Jason Carr

Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals Inc (NASDAQ: KALA) on December 22 and set a price target of $46. The company’s shares opened today at $17.25.

According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 11.2% and a 46.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Kala Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $35.

Based on Kala Pharmaceuticals Inc’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $0 and GAAP net loss of $10.18 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $5.25 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R.